Table 1.
STEMI (N=60 712) | NSTEMI (N=119 656) | |||||
---|---|---|---|---|---|---|
Women (n=20 140) | Men (n=40 572) | Difference in Means/Proportions (95% CI)a | Women (n=45 254) | Men (n=74 402) | Difference in Means/Proportions (95% CI)a | |
Mean (SD) age, y | 73.7 (12.2) | 66.5 (12.1) | −7.22 (−7.43 to −7.02)b | 75.6 (11.5) | 70.4 (11.9) | −5.19 (−5.33 to −5.05)b |
Year of hospitalization, n (%) | ||||||
2003–2005 | 5903 (29.3) | 11 208 (27.6) | 1.69 (0.26–3.12)b | 13 054 (28.9) | 21 099 (28.4) | 0.49 (−0.50 to 1.48) |
2006–2008 | 5549 (27.6) | 10 911 (26.9) | 0.66 (−0.78 to 2.10) | 12 704 (28.1) | 20 722 (27.9) | 0.22 (−0.77 to 1.21) |
2009–2011 | 5263 (26.1) | 11 217 (27.7) | −1.52 (−3.00 to −0.07)b | 11 675 (25.8) | 19 448 (26.1) | −0.34 (−1.34 to 0.67) |
2012–2013 | 3425 (17.0) | 7236 (17.8) | −0.82 (−2.36 to 0.72) | 7821 (17.3) | 13 133 (17.7) | −0.37 (−1.43 to 0.69) |
Risk factors, n (%) | ||||||
Diabetes mellitus | 3524 (17.5) | 5972 (14.7) | 2.78 (1.24–4.32)b | 10 510 (23.2) | 16 384 (22.0) | 1.2 (0.17–2.23)b |
Hypertension | 9724 (48.3) | 14 701 (36.2) | 12.05 (10.80–13.31)b | 24 456 (54.0) | 33 436 (44.9) | 9.1 (8.28–9.92)b |
Current or ex‐smoker | 8574 (47.3) | 24 075 (63.8) | −16.47 (−17.70 to −15.25)b | 16 569 (41.2) | 42 269 (62.0) | −20.78 (21.66 to −19.90)b |
Prior cardiovascular diseases, n (%) | ||||||
Myocardial infarction | 2346 (11.7) | 5278 (13.0) | −1.36 (−2.94 to 0.22) | 10 126 (22.4) | 19 192 (25.8) | −3.42 (−4.44 to −2.40)b |
Heart failure | 1269 (6.3) | 1526 (3.8) | 2.54 (0.90–4.18)b | 6170 (13.6) | 8382 (11.3) | 2.36 (1.27–3.45)b |
PCI | 721 (3.6) | 2440 (6.0) | −2.43 (−4.08 to −0.78)b | 2857 (6.3) | 7763 (10.4) | −4.12 (−5.24 to −3.00)b |
CABG | 415 (2.1) | 1626 (4.0) | −1.95 (−3.62 to −0.28) | 2493 (5.5) | 8699 (11.7) | −6.18 (−7.30 to −5.06)b |
Cerebrovascular disease | 1775 (8.8) | 2746 (6.8) | 2.04 (0.42–3.66)b | 5335 (11.8) | 8189 (11.0) | 0.78 (−0.32 to 1.88) |
PVD | 833 (4.1) | 1287 (3.2) | 0.97 (−0.69 to 2.63) | 3121 (6.9) | 5041 (6.8) | 0.12 (−1.01 to 1.25) |
Other comorbidities, n (%) | ||||||
Chronic renal failure | 372 (1.9) | 717 (1.8) | 0.08 (−1.60 to 1.76) | 1522 (3.4) | 2991 (4.0) | −0.66 (−1.81 to −0.49) |
COPD | 1358 (6.7) | 1656 (4.1) | 2.66 (1.02–4.30)b | 4130 (9.1) | 5208 (7.0) | 2.13 (1.01–3.25)b |
Presentation characteristics | ||||||
Systolic BP, mm Hg, mean (SD) | 140.0 (31.4) | 140.9 (29.6) | 0.87 (0.32–1.43)b | 150.4 (30.8) | 148.5 (28.6) | −1.83 (−2.21 to −1.46)b |
Systolic BP, ≤90 mm Hg, n (%) | 1032 (5.1) | 1555 (3.8) | 1.29 (−0.36 to 2.94) | 924 (2.0) | 1323 (1.8) | 0.26 (−0.90 to 1.42) |
Heart rate, beats/min, mean (SD) | 79.7 (22.4) | 76.8 (21.0) | −2.87 (−3.26 to −2.47)b | 86.5 (24.5) | 81.3 (23.9) | −5.24 (−5.54 to −4.93)b |
Heart rate, >110 beats/min, n (%) | 1430 (8.4) | 2068 (6.0) | 2.39 (0.63–4.15)b | 5521 (14.4) | 6380 (10.1) | 4.31 (3.13–5.49)b |
ST‐segment deviation, n (%) | 18 841 (93.8) | 37 909 (93.8) | 0 (−0.42 to 0.42) | 16 852 (37.9) | 26 483 (36.3) | 1.64 (0.71–2.57)b |
In‐hospital course, n (%) | ||||||
Cardiac arrest | 1265 (6.3) | 2491 (6.1) | 0.14 (−1.50 to 1.78) | 961 (2.1) | 1878 (2.5) | −0.41 (−1.56 to 0.74) |
Use of a loop diuretic | 5703 (28.5) | 8181 (20.3) | 8.23 (6.77–9.70)b | 13 511 (30.0) | 16 177 (21.9) | 8.15 (7.15–9.15)b |
Reperfusion | 13 768 (68.5) | 32 093 (79.2) | −10.7 (−11.60 to −9.81)b | NA | NA | NA |
Revascularization | 13 023 (64.7) | 32 446 (80.0) | −15.31 (−16.24 to −14.38)b | 14 528 (32.1) | 37 616 (50.6) | −18.46 (−19.37 to −17.55)b |
Treatments at discharge | ||||||
Aspirin | 17 304 (87.1) | 36 873 (91.8) | −4.66 (−5.23 to −4.09)b | 38 451 (85.7) | 65 956 (89.4) | −3.68 (−4.10 to −3.26)b |
β‐Blocker | 16 530 (83.1) | 35 417 (88.0) | −4.89 (−5.55 to −4.23)b | 37 535 (83.6) | 63 518 (86.0) | −2.37 (−2.83 to −1.91)b |
Statin | 14 612 (73.5) | 34 431 (85.6) | −12.12 (−12.93 to −11.31)b | 30 419 (67.8) | 58 677 (79.5) | −11.68 (−12.30 to −11.06)b |
ACEi or ARB | 13 070 (70.3) | 29 372 (77.7) | −7.35 (−8.27 to −6.43)b | 27 271 (65.3) | 47 912 (69.4) | −4.15 (−4.85 to −3.45)b |
P2Y12 inhibitor | 14 176 (71.2) | 32 519 (80.8) | −9.56 (−10.42 to −8.70)b | 26 329 (58.6) | 49 396 (66.8) | −8.23 (−8.96 to −7.50)b |
Difference in means for continuous variables and proportions for categorical variables. Reperfusion comprises fibrinolysis or primary PCI. Revascularization comprises PCI or CABG surgery. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; NSTEMI indicates non–ST‐segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST‐segment–elevation myocardial infarction.
significance level of p value <0.05..
Significance level <0.05.